{
    "eid": "2-s2.0-85101465271",
    "title": "In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy",
    "cover-date": "2021-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cellular and Molecular Neuroscience",
            "@code": "2804",
            "@abbrev": "NEUR"
        }
    ],
    "keywords": [
        "Biomarkers",
        "Fatigue and physiosomatic symptoms",
        "Inflammation",
        "Major depression",
        "Neuroimmunomodulation",
        "Schizophrenia"
    ],
    "authors": [
        "Hussein Kadhem Al-Hakeim",
        "Rana Fadhil Mousa",
        "Arafat Hussein Al-Dujaili",
        "Michael Maes"
    ],
    "citedby-count": 5,
    "ref-count": 69,
    "ref-list": [
        "High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations with Interleukin-6, Symptom Domains, and Neurocognitive Impairments",
        "Construction of a neuro-immune-cognitive pathway-phenotype underpinning the phenome of deficit schizophrenia",
        "The Neuroimmune and neurotoxic fingerprint of Major neurocognitive psychosis or deficit schizophrenia: a supervised machine learning study",
        "Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia",
        "HMGB1 is a therapeutic target for sterile inflammation and infection",
        "The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations",
        "Interleukin-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance",
        "Inhibitory effects of endomorphin-2 on excitatory synaptic transmission and the neuronal excitability of sacral parasympathetic preganglionic neurons in young rats",
        "Dynorphin and the kappa opioid Receptor\u2019s role in the symptomatology of schizophrenia: a review of the evidence",
        "Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists",
        "Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning",
        "Decision criteria for soft independent modelling of class analogy applied to near infrared data",
        "Identifying a neuroanatomical signature of schizophrenia, reproducible across sites and stages, using machine learning with structured sparsity",
        "Dopamine synthesis capacity in patients with treatment-resistant schizophrenia",
        "Wnts in action: from synapse formation to synaptic maintenance",
        "HMGB1 in development and diseases of the central nervous system",
        "Profiling cognitive impairment in treatment-resistant schizophrenia patients",
        "HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease",
        "HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration",
        "Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review",
        "Advantages and disadvantages of combination treatment with antipsychotics: ECNP consensus meeting, march 2008, Nice",
        "A rating scale for depression",
        "The clinical global impression\u2013schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia",
        "Multiple targets of -opioid receptor-mediated presynaptic inhibition at primary afferent a - and C-fibers",
        "Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology",
        "Novel opioid peptides endomorphin-1 and endomorphin-2 are present in mammalian immune tissues",
        "Opioid peptides Endomorphin-1 and Endomorphin-2 in the immune system in humans and in a rodent model of inflammation",
        "Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia",
        "Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia",
        "Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine",
        "The positive and negative syndrome scale (PANSS) for schizophrenia",
        "The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery",
        "Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses",
        "The dysphoric component of stress is encoded by activation of the dynorphin \u03ba-opioid system",
        "Endomorhin peptides: pharmacological and functional implications of these opioid peptides in the brain of mammals",
        "Definitions of response and remission in schizophrenia: recommendations for their use and their presentation",
        "Inducible expression of functional mu opioid receptors in murine dendritic cells",
        "The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6",
        "Dysfunctional Wnt/\u03b2-catenin signaling contributes to blood\u2013brain barrier breakdown in Alzheimer\u2019s disease",
        "A generalized cognitive decline (GCoDe) partly mediates the effects of Neuro-immune and Neuro-oxidative toxicity on the Symptomatome and lowered quality of life in (deficit) schizophrenia",
        "Clinical subtypes of unipolar depression: part II. Quantitative and qualitative clinical differences between the vital and nonvital depression groups",
        "Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflamatory process during that illness",
        "Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects",
        "Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs",
        "Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression",
        "Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor",
        "Increased levels of plasma tumor necrosis factor-\u03b1 mediate schizophrenia symptom dimensions and neurocognitive impairments and are inversely associated with natural IgM directed to malondialdehyde and Paraoxonase 1 activity",
        "Reversal of synapse degeneration by restoring Wnt signaling in the adult hippocampus",
        "The endogenous opioid system in schizophrenia and treatment resistant schizophrenia: increased plasma Endomorphin 2, and \u03ba and \u03bc opioid receptors are associated with Interleukin-6",
        "The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia",
        "Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats",
        "Role of the mu-opioid receptor in opioid modulation of immune function",
        "High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance",
        "Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis",
        "HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism",
        "The brief psychiatric rating scale",
        "Is soft independent modeling of class analogies a reasonable choice for supervised pattern recognition?",
        "The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia",
        "Endomorphin-2- and Neurotensin- based chimeric peptide attenuates airway inflammation in mouse model of nonallergic asthma",
        "Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline",
        "Role of kappa opioid receptors in symptoms of schizophrenia: what is the neurobiology?",
        "Eotaxin, an endogenous cognitive deteriorating chemokine (ECDC), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients",
        "A new schizophrenia model: immune activation is associated with the induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions",
        "The macrophage-T-lymphocyte theory of schizophrenia: additional evidence",
        "Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation",
        "Disability and schizophrenia: a systematic review of experienced psychosocial difficulties",
        "A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale)",
        "Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics"
    ],
    "affiliation": [
        {
            "affiliation-city": "Kufa",
            "@id": "60071160",
            "affilname": "University of Kufa",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071160",
            "affiliation-country": "Iraq"
        },
        {
            "affiliation-city": "Karbala",
            "@id": "60107657",
            "affilname": "University of Kerbala",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107657",
            "affiliation-country": "Iraq"
        },
        {
            "affiliation-city": "Plovdiv",
            "@id": "60031890",
            "affilname": "Medical University of Plovdiv",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031890",
            "affiliation-country": "Bulgaria"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Geelong",
            "@id": "60018805",
            "affilname": "Deakin University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018805",
            "affiliation-country": "Australia"
        }
    ],
    "funding": []
}